Retrospective observational studies previously reported improvement among patients with Type 2 diabetes mellitus using drugs specifically designed to inhibit DPP4 activity and COVID-19 in severe outcomes and mortality. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.